Mark D. Matteucci

Nessuna posizione attualmente

70 anni

Health Technology

Finance

Consumer Services

Profilo

Dr. Mark D.
Matteucci is Chief Scientific Officer & SVP-Discovery Research at Threshold Pharmaceuticals, Inc. Dr. Matteucci was previously employed as a Director-Bioorganic Chemistry by Gilead Sciences, Inc. He received his undergraduate degree from the Massachusetts Institute of Technology and a doctorate degree from The University of Colorado.

Precedenti posizioni note di Mark D. Matteucci

Società	Posizione	Fine
GILEAD SCIENCES, INC.	Corporate Officer/Principal	01/01/1999
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Direttore Tecnico/Scientifico/R&S	-

Vedi nel dettaglio l'esperienza di Mark D. Matteucci

Formazione di Mark D. Matteucci

Massachusetts Institute of Technology	Undergraduate Degree
The University of Colorado	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Mark D. Matteucci

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
GILEAD SCIENCES, INC.	Health Technology

Aziende private	1
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Health Technology